PMID- 11053626
OWN - NLM
STAT- MEDLINE
DCOM- 20010111
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 100
IP  - 2
DP  - 2000 Oct 15
TI  - The role of low-molecular-weight heparins in arterial diseases: optimizing 
      antithrombotic therapy.
PG  - V131-9
AB  - On the basis of current evidence, all patients with acute coronary syndromes 
      should receive optimized medical therapy, whether or not they ultimately undergo 
      an invasive revascularization procedure, to improve both clinical outcomes and 
      cost effectiveness. While standard aspirin and unfractionated heparin (UFH) have 
      improved short-term outcomes, they do not eliminate the risk of recurrent 
      ischemic episodes. The recent introduction of platelet fibrinogen receptor 
      antagonists and low-molecular-weight heparins (LMWHs) has offered an opportunity 
      to develop more aggressive antithrombotic regimens. The LMWHs have been 
      thoroughly evaluated in unstable angina and non-Q wave myocardial infarction 
      (UA/NQMI), and have demonstrated improved efficacy compared to standard UFH, 
      without an increase in major complications caused by bleeding. Experience has 
      also been gathered using LMWHs in other arterial diseases (such as pregnant 
      patients with prosthetic heart valves) and as an adjunctive therapy with 
      thrombolytics for acute myocardial infarction. Lastly, studies are currently 
      underway evaluating LMWHs in patients with atrial fibrillation.
FAU - Cohen, M
AU  - Cohen M
AD  - Division of Cardiology, Hahnemann University Hospital, Philadelphia, PA 
      19102-1192, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
SB  - IM
MH  - Anticoagulants/adverse effects/standards/therapeutic use
MH  - Coronary Disease/complications/*drug therapy
MH  - Female
MH  - Fibrinolytic Agents/standards/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/standards/*therapeutic use
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/complications/drug therapy
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pregnancy
RF  - 52
EDAT- 2000/10/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/29 11:00
PHST- 2000/10/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/29 11:00 [entrez]
AID - S0049384800002735 [pii]
AID - 10.1016/s0049-3848(00)00273-5 [doi]
PST - ppublish
SO  - Thromb Res. 2000 Oct 15;100(2):V131-9. doi: 10.1016/s0049-3848(00)00273-5.